 Trevena Inc NASDAQ: TRVN has announced that the National Institute on Drug Abuse NIDA, part of the NIH, has resumed recruitment for its proof-of-concept study for TRV734. The Company has collaborated with NIDA to evaluate TRV734 as potential maintenance therapy for opioid use disorder. 